Nature's Sunshine (NASDAQ:NATR) Misses Q2 CY2026 Sales Expectations, Stock Drops 14.3%
Nature’s Sunshine (NASDAQ: NATR) reported Q2 CY2026 sales of $117 million, up 1.9% year on year, missing Wall Street expectations. Full-year revenue guidance was $495 million at the midpoint, about 2.5% below estimates. Non-GAAP EPS was $0.21, 22.2% below consensus. The stock fell 14.3% to $17.48.
How this was made
The 30-second read
Why it matters
Traders can update models based on the disclosed Q2 revenue miss, FY revenue guidance shortfall versus estimates, and non-GAAP EPS miss, all corroborated by a same-day 14.3% stock drop.
Market read
A clear earnings-and-guidance miss with immediate downside reaction provides a fresh basis for near-term estimate revisions and positioning.
What to watch
The article notes gross margin narrowly beat expectations, which could limit downside if investors over-penalize revenue weakness; also free cash flow turned negative after being positive a year ago, which may be timing-related rather than structural.
Background
Nature’s Sunshine is a nutritional and personal care products company reporting Q2 CY2026 results and full-year revenue guidance.
Ticker impact
Nature’s Sunshine reported Q2 CY2026 sales of $117M, up 1.9% YoY, missing expectations and sending the stock down 14.3% to $17.48.
Bearish bias for the next several sessions as traders reprice FY revenue and margin expectations after the Q2 miss.
The article provides concrete, time-sensitive datapoints: Q2 revenue miss, FY midpoint revenue guidance 2.5% below estimates, non-GAAP EPS 22.2% below consensus, and an immediate 14.3% drop.
Market effects
Signals weaker demand and margin pressure risk for small-cap consumer staples/wellness brands, potentially raising scrutiny on cash generation.
No specific regional shock beyond the company’s claim of constant-currency growth across most geographies.
Limited; this is company-specific guidance and performance with no broader macro/regulatory linkage stated.
Counterpoint
Despite the miss, management cited constant-currency sales growth of 4% across nearly all regions, suggesting the headline miss may be partly estimate-driven rather than demand collapse.
Key entities
- companyNature’s Sunshine
Reported Q2 CY2026 revenue of $117M (+1.9% YoY) and FY revenue guidance of $495M midpoint, both below expectations; non-GAAP EPS $0.21 missed consensus.
- executiveKen Romanzi
CEO statement attributing performance to constant-currency sales growth of 4% across nearly all geographic regions.
